Investor Relations
About Vivani
Vivani Medical is an emerging biopharmaceutical company developing a pipeline of miniature, ultra long-term drug implants with its proprietary NanoPortal™ platform technology for obesity/weight management and other chronic diseases.
Vivani’s lead drug implant candidates are designed to improve medication adherence and deliver smooth consistent therapeutic levels of GLP-1 – the same class of active pharmaceutical ingredients in Ozempic®, Trulicity® and Wegovy® – for 6 months, 12 months, or longer with a single administration. NPM-139 and NPM-133, are miniature, six-month, GLP-1 (semaglutide) implants under development for obesity/chronic weight management and the treatment of type 2 diabetes, respectively.
In 2025, Vivani completed LIBERATE-1, the first-in-human study of a GLP-1 (exenatide) with our proprietary NanoPortal implant technology. This clinical study successfully met its primary objectives to evaluate the implants’ safety and tolerability profile and characterize the drug’s pharmacokinetic profile over a 9-week duration. Concurrently with the completion of LIBERATE-1, Vivani reported new NPM-139 (semaglutide implant) preclinical feasibility data showing approximately 20% weight loss maintained longer than 6 months with a single implant and continuing to support the potential for once-yearly administration.
Based on these data, Vivani has prioritized the clinical development of NPM-139 (semaglutide implant) for the treatment of chronic weight management. The initial clinical study, also known as SLIM-1 (Semaglutide ultra Long-acting IMplant in chronic weight management) is on-track to initiate in mid-2026 with top-line data anticipated by the end of 2026.
NanoPortal™ has broad potential application across a range of molecule types including peptide therapeutics.